Comparative Effectiveness and Safety of Thalidomide and Lenalidomide in Patients with Multiple Myeloma in the United States of America: A Population-Based Cohort Study

Lenalidomide initiators had a significantly lower risk of developing peripheral neuropathy compared with thalidomide initiators among 1,264 multiple myeloma patients, with no difference in mortality rates between the two treatments. These findings suggest that while thalidomide and lenalidomide are equivalent for survival outcomes, lenalidomide presents a safety advantage regarding neurotoxicity in routine clinical practice.